RASA1/ NF1-Mutant Lung Cancer: Racing to the Clinic?

Clin Cancer Res. 2018 Mar 15;24(6):1243-1245. doi: 10.1158/1078-0432.CCR-17-3597. Epub 2018 Jan 17.

Abstract

Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1/NF1-mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. Clin Cancer Res; 24(6); 1243-5. ©2018 AACRSee related article by Hayashi et al., p. 1436.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Humans
  • Lung Neoplasms / genetics*
  • Mutation / drug effects
  • Protein Kinase Inhibitors
  • Smoking
  • p120 GTPase Activating Protein / genetics

Substances

  • Protein Kinase Inhibitors
  • RASA1 protein, human
  • p120 GTPase Activating Protein